Anti-Human CD38 Reference Antibody (Mezagitamab, RUO)
- Catalog number: BS10116
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Mezagitamab (BS10116) is a research-grade recombinant antibody targeting CD38. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CyclicADP-ribosehydrolase1,ADP-ribosylcyclase/cyclicADP-ribosehydrolase1,cADPrhydrolase1,2'-phospho-ADP-ribosylcyclase/2'-phospho-cyclic-ADP-ribosetransferase,T10,2'-phospho-cyclic-ADP-ribosetransferase,CD38,ADPRC1,ADP-ribosylcyclase1,2'-phospho-ADP-ribosylcyclase
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: TAK-079,CAS:2227490-52-8
Background: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38/ADPRC 1) is a ~34 kDa protein. Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity. CD38 is the therapeutic target of daratumumab (Darzalex).
References:
1. Tohgo, A. et al. (1994) The Journal of biological chemistry 269, 28555-7. PMID: 796180
2. Takasawa, S. et al. (1993) The Journal of biological chemistry 268, 26052-4. PMID: 8253715
3. Moreschi, I. et al. (2006) Biochemical and biophysical research communications 345, 573-80. PMID: 16690024
4. Deaglio, S. et al. (1998) Journal of immunology (Baltimore, Md. : 1950) 160, 395-402. PMID: 9551996
5. Frasca, L. et al. (2006) Blood 107, 2392-9. PMID: 16293598
6. Deaglio, S. et al. (2001) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15, 580-2. PMID: 11259373
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-lambda
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CyclicADP-ribosehydrolase1,ADP-ribosylcyclase/cyclicADP-ribosehydrolase1,cADPrhydrolase1,2'-phospho-ADP-ribosylcyclase/2'-phospho-cyclic-ADP-ribosetransferase,T10,2'-phospho-cyclic-ADP-ribosetransferase,CD38,ADPRC1,ADP-ribosylcyclase1,2'-phospho-ADP-ribosylcyclase
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: TAK-079,CAS:2227490-52-8
Background: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38/ADPRC 1) is a ~34 kDa protein. Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity. CD38 is the therapeutic target of daratumumab (Darzalex).
References:
1. Tohgo, A. et al. (1994) The Journal of biological chemistry 269, 28555-7. PMID: 796180
2. Takasawa, S. et al. (1993) The Journal of biological chemistry 268, 26052-4. PMID: 8253715
3. Moreschi, I. et al. (2006) Biochemical and biophysical research communications 345, 573-80. PMID: 16690024
4. Deaglio, S. et al. (1998) Journal of immunology (Baltimore, Md. : 1950) 160, 395-402. PMID: 9551996
5. Frasca, L. et al. (2006) Blood 107, 2392-9. PMID: 16293598
6. Deaglio, S. et al. (2001) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15, 580-2. PMID: 11259373
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Mezagitamab
